The purpose of this legislation is to improve the process of developing and approving drugs for rare diseases. It aims to establish a structured way for medical experts, drug developers, and patient organizations to come together and discuss scientific challenges and solutions in drug development. This initiative is particularly focused on ensuring that the voices of those affected by rare diseases are heard and considered in the drug approval process. Key provisions of the legislation include the creation of externally led, science-focused drug development meetings.